首页 | 本学科首页   官方微博 | 高级检索  
     

Reversal of HCC Drug Resistance by Using Hammerhead Ribozymes against Multidrug Resistance 1 Gene
引用本文:乔森 王海 陈孝平. Reversal of HCC Drug Resistance by Using Hammerhead Ribozymes against Multidrug Resistance 1 Gene[J]. 华中科技大学学报(医学英德文版), 2005, 25(6): 662-664. DOI: 10.1007/BF02896164
作者姓名:乔森 王海 陈孝平
作者单位:[1]The Hepatic Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan , 430030, China [2]The Liver Transplantation Center, Nanjing Medical University, Nanjing 210029, China
基金项目:This work was supported by a grant for Key Programs of Ministry of Public Health of China (No. 3212001).
摘    要:To reverse multidrug resistance(MDR) of HepG2 by anti-MDR1 hammerhead ribozyme, an anti-MDR1 hammerhead ribozyme was developed and delivered to P-gp-overproducing human hepatocarcinoma cell line HepG2 by a retroviral vector containing RNA polymerase Ⅲ promoter. The expression of mdrl/Pgp and Rz was detected in HepG2, HepG2 muhidrug-resistant cell line and HepG2 Rz-transfected cells by semi-quantitative RT-PCR and Western blot methods. Moreover, MTT assay was employed to detect the sensitivity of these ribozyme-transfected cells, and Rhodamine123 (Rh123) was used to test the function of Pgp. The Rz- transfected HepG2 cells became doxorubicin-sensitive, which was concomitant with the decreased MDR1 expression. The study showed that the retrovirus vector encoding the anti-MDR1 ribozyme may be applicable to the treatment of MDR cells.

关 键 词:药物抵抗 核糖酶 P-糖蛋白 肿瘤
收稿时间:2005-10-27

Reversal of HCC drug resistance by using hammerhead ribozymes against multidrug resistance 1 gene
Qiao Sen,Wang Hai,Chen Xiaoping. Reversal of HCC drug resistance by using hammerhead ribozymes against multidrug resistance 1 gene[J]. Journal of Huazhong University of Science and Technology. Medical sciences, 2005, 25(6): 662-664. DOI: 10.1007/BF02896164
Authors:Qiao Sen  Wang Hai  Chen Xiaoping
Affiliation:1. The Hepatic Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan , 430030, China
2. The Liver Transplantation Center, Nanjing Medical University, Nanjing 210029, China
Abstract:Summary To reverse multidrug resistance (MDR) of HepG2 by anti-MDR1 hammerhead ribozyme, an anti-MDR1 hammerhead ribozyme was developed and delivered to P-gp-overproducing human hepatocarcinoma cell line HepG2 by a retroviral vector containing RNA polymerase III promoter. The expression of mdr1/Pgp and Rz was detected in HepG2, HepG2 multidrug-resistant cell line and HepG2 Rz-transfected cells by semi-quantitative RT-PCR and Western blot methods. Moreover, MTT assay was employed to detect the sensitivity of these ribozyme-transfected cells, and Rhodamine 123 (Rh123) was used to test the function of Pgp. The Rz-transfected HepG2 cells became doxorubicin-sensitive, which was concomitant with the decreased MDR1 expression. The study showed that the retrovirus vector encoding the anti-MDR1 ribozyme may be applicable to the treatment of MDR cells. QIAO Sen, male, born in 1965, M. D., Ph.D. This work was supported by a grant for Key Programs of Ministry of Public Health of China (No. 3212001).
Keywords:liver neoplasms   carcinoma   P-glycoprotein   multi-drug resistance   ribozyme
本文献已被 CNKI 维普 万方数据 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号